Compounded Tirzepatide: What Is Actually In It?
Compounded tirzepatide is sold online as a cheaper equivalent to the licensed medicine. The selling point is often the same: the same active ingredient at a lower price, sometimes without a prescription.
For an unlicensed product bought from an unregulated source, there is no reliable way for the buyer to verify its ingredients, strength or sterility.
This page explains what these products are, what UK regulators have found inside them, and why an identical active ingredient on a label does not make something the same medicine.
Key things to know
- There is no authorised compounded tirzepatide product marketed for weight loss in the UK. Unlicensed medicines can exist under the UK ‘specials’ framework in specific clinical circumstances, but that is very different from buying compounded tirzepatide online.
- Tirzepatide is a prescription-only medicine, so supply without a prescription is unlawful.
- No authorised tirzepatide product is supplied as a powder for you to mix at home.
- In October 2025 the MHRA dismantled the UK's first illicit weight loss medicine factory, seizing 2,000 unlicensed pens labelled as tirzepatide and raw chemical ingredients.
- A second enforcement operation followed in February 2026, seizing nearly 2,000 more doses.
- The MHRA has stated plainly that unlicensed products carry no guarantees on dose, ingredients or sterility.
- A ‘research use only’ or ‘not for human consumption’ disclaimer does not make an unlicensed product suitable or lawful for human use
What people mean by compounded tirzepatide
The term comes from the United States, where pharmacies were permitted for a period to prepare versions of certain medicines during official shortages. That framework does not transfer to the UK, and the shortage conditions that allowed it have largely ended in any case.
In the UK, what is actually being sold under that name falls into three groups.
Unlicensed products made to look like the real thing. Pens or vials labelled as tirzepatide, produced outside any authorised manufacturing facility.
Research peptides. Sold in powder form with a disclaimer stating they are for laboratory use and not for human consumption. The disclaimer exists for the seller, not the buyer.
Falsified products. Counterfeit packaging designed to pass as the licensed medicine.
These products should not be confused with medicines legitimately prepared under the UK’s regulated ‘specials’ framework. The UK has a route for unlicensed medicines prepared for individual patients with genuine clinical need, and buying peptides online from a website is not it.
The detail that settles it
Here is a check anyone can apply without any technical knowledge.
No authorised tirzepatide product is supplied as a powder for you to reconstitute at home. The licensed medicine comes ready to use.
So if you are offered a vial of powder plus a separate vial of liquid to mix, you are not being sold a cheaper version of the licensed medicine. You are being sold something else entirely, by someone who knows that.
This single test rules out a large share of what is sold online, and it does not require you to assess anything about the seller.
What UK regulators have actually found
This is not a theoretical risk. There is a documented enforcement record.
In October 2025, the MHRA's Criminal Enforcement Unit raided a warehouse near Northampton and shut down what it described as the first illicit weight loss medicine production facility found in the UK. The agency said it was the largest single seizure of trafficked weight loss medicines recorded by any law enforcement agency worldwide.
Officers seized more than 2,000 unlicensed pens labelled as tirzepatide and retatrutide awaiting dispatch, tens of thousands of empty pens ready to be filled, raw chemical ingredients, packaging and manufacturing equipment.
A second operation followed in February 2026, with nearly 2,000 further doses seized across two English counties, alongside equipment, suspected pharmaceutical ingredients, packaging and vehicles.
The presence of raw chemical ingredients and manufacturing equipment shows that the operation involved the production or preparation of unlicensed medicines outside the authorised pharmaceutical supply chain
The MHRA's own summary of the risk is blunt: unlicensed products offer no guarantees on dose, ingredients or sterility.
What has turned up inside
Separately, the MHRA has reported that some illegally supplied weight loss pens were found to contain insulin rather than the labelled medicine. For someone without diabetes, that causes dangerously low blood sugar, and people have been admitted to hospital as a result.
It has also confirmed that a falsified weight management product reached patients through an online pharmacy in the UK. Professional-looking packaging and a professional-looking website prove nothing.
Products labelled as retatrutide have appeared alongside tirzepatide in these seizures. Retatrutide is not authorised for use in the UK, so products sold to consumers as retatrutide are not authorised medicines.
Why the same active ingredient is not the same medicine
This is the argument that persuades people, so it deserves a proper answer rather than a dismissal.
A licensed medicine is not simply a molecule. It is a molecule of verified identity and purity, at a verified concentration, in a sterile formulation, in a container tested for compatibility, with a known shelf life under stated storage conditions, produced under inspected manufacturing standards, in traceable batches that can be recalled.
Those characteristics are all part of what makes a medicine a controlled, reliable medicinal product.
Identity and purity. There is no way to know whether a powder contains tirzepatide, how much of it, or what else came along with it. Peptide synthesis produces related impurities, and controlling them is a manufacturing discipline rather than an assumption.
Salt form. Peptides are supplied in different salt forms, and the form used in an authorised product is specified. Different salt or formulation forms can have different pharmaceutical properties, so the form and formulation of the active ingredient matter
Concentration. The amount of active substance per unit of liquid determines the dose. An unverified product provides no reliable basis for that.
Sterility. This is injected under the skin. Sterile manufacture requires controlled conditions, and bacterial contamination or endotoxins in an injected product cause serious harm.
Stability and storage. Peptides degrade. The licensed product has tested storage conditions and a known shelf life. An unlicensed one has neither, and may have spent weeks in transit at unknown temperatures.
Traceability. If something goes wrong with a licensed medicine, the batch can be identified, reported through the Yellow Card scheme and recalled. An unregulated product does not provide the same reliable batch traceability, recall mechanisms or pharmacovigilance protections as a licensed medicine
The dosing problem
Products sold as powder require mixing and measuring before use. That introduces a category of harm that does not exist with the licensed medicine.
Errors in this process have led to people receiving many times the intended amount. We are not going to describe how reconstitution works, because this page is not a guide to doing it safely, and there is no safe version of doing it with an unverified product.
The relevant point is that the licensed medicine is supplied ready to use precisely so that this step does not exist.
The legal position
Tirzepatide is a prescription-only medicine in the UK and must be supplied through the regulated medicines system. Unlicensed manufacture and supply are subject to specific legal requirements, including licensing and the rules governing ‘specials’
The products targeted in the MHRA enforcement operations described above were unlicensed medicines being manufactured or supplied outside that regulated framework.
For the buyer, the practical consequences are that there is no recourse if something goes wrong, no route to compensation, and no clinician who knows what you have taken.
If you have already used one
This is a common position and the sensible response is not to feel foolish about it.
If you feel unwell, seek medical advice and say what you took. Bring the packaging if you have it. Clinicians need the information, not an explanation, and they have seen this before.
If you took something and felt fine, it is still worth mentioning at your next appointment, particularly if you are now considering licensed treatment.
Do not continue while arranging an assessment. Tell the prescriber exactly what you used and when. They can then decide whether it is appropriate to start or change treatment and whether any monitoring is needed.
Keep the product and the packaging. Suspected counterfeit or unlicensed medicines can be reported to the MHRA, and the physical product is useful to them.
Seek urgent medical attention for symptoms of low blood sugar such as shakiness, sweating, confusion and palpitations, for severe and persistent stomach pain that may spread through to your back, for swelling of the face, lips, tongue or throat, for difficulty breathing, or for signs of infection at an injection site including spreading redness, heat, swelling or fever.
How to check a legitimate supply
Five checks, in order of usefulness.
- Is the seller a registered pharmacy? Pharmacies operating in Great Britain appear on the General Pharmaceutical Council register, which is publicly searchable. Check the registration number and trading address against the register rather than trusting a logo.
- Were you asked detailed clinical questions about your medical history, other medicines and other conditions before anything was supplied?
- Did a prescriber review your answers, with the ability to decline or ask for more information?
- Does the product arrive in original manufacturer packaging with a patient information leaflet?
- Is it ready to use? Anything requiring you to mix a powder is not the licensed medicine.
Warning signs: no prescription required, sales through social media or messaging apps, products described as research grade or not for human consumption, bulk discounts on a prescription medicine, shipping from outside the UK regulatory system, and prices far below what registered pharmacies charge.
What the price difference actually buys
The honest reason people consider these products is cost, and that deserves acknowledging rather than lecturing about.
What the difference pays for is not branding. It is verified identity and purity, a known concentration, sterile manufacture, tested storage and shelf life, inspected production, traceable batches, a patient information leaflet, a prescriber who assessed whether the medicine suits you, and a route to report problems.
Remove all of that and the remaining product is cheaper because it is a different thing. If cost is the obstacle, the better conversation is with a pharmacist about what options exist, rather than with a website selling powder.
Medical Disclaimer
This article is for general information only. It is not medical advice and it does not replace an individual assessment by an appropriately qualified healthcare professional.
Tirzepatide is a prescription-only medicine in the UK. It should only be supplied following a clinical assessment and prescription from an appropriately qualified prescriber, and used under their supervision. Treatment suitability depends on an individual clinical assessment, and results vary between individuals.
Do not obtain prescription medicines outside the regulated system. Products supplied that way are not covered by MHRA oversight, and their contents, strength, sterility and storage cannot be relied upon.
If you have used an unlicensed product and feel unwell, seek medical advice and say what you took. Seek urgent medical attention for symptoms of low blood sugar, severe and persistent stomach pain that may spread to your back, swelling of the face, lips, tongue or throat, difficulty breathing, or signs of infection at an injection site.
Suspected counterfeit or unlicensed medicines can be reported to the MHRA. Suspected side effects can be reported through the Yellow Card scheme.
Frequently Asked Questions
What is in compounded tirzepatide?
For an unlicensed product obtained from an unregulated source, there is no reliable way for the buyer to verify exactly what it contains. These products are not batch tested, their contents are not verified, and the MHRA has stated that unlicensed products carry no guarantees on dose, ingredients or sterility.
In enforcement raids, the agency has seized raw chemical ingredients and tens of thousands of empty pens being filled outside any authorised facility.
Is compounded tirzepatide legal in the UK?
There is no authorised compounded tirzepatide product marketed for weight loss in the UK. The UK does have a regulated framework for certain unlicensed medicines, known as “specials”, which can be supplied in specific clinical circumstances when a licensed medicine cannot meet an individual patient's needs.
This is very different from buying a product labelled “compounded tirzepatide” from an unregulated website or social media seller.
Is it the same as Mounjaro if it has the same active ingredient?
No. A licensed medicine is a verified substance at a verified concentration, sterile, stable, in tested packaging, made under inspected standards and in traceable batches.
An unverified product may contain a different amount, a different salt form, impurities from synthesis, or something else entirely.
How can I tell if a product is not the real thing?
The simplest test is whether it comes as a powder you have to mix. No authorised tirzepatide product is supplied that way.
Also check whether the seller is on the General Pharmaceutical Council register and whether you were asked clinical questions before supply.
What has the MHRA found in these products?
In October 2025 it dismantled the UK's first illicit weight loss medicine factory, seizing over 2,000 unlicensed pens labelled as tirzepatide and retatrutide, tens of thousands of empty pens and raw chemicals. A second operation in February 2026 seized nearly 2,000 further doses.
Separately, some illegally supplied pens have been found to contain insulin rather than the labelled medicine, causing dangerously low blood sugar and hospital admissions.
What about research peptides sold as not for human consumption?
The disclaimer protects the seller rather than the buyer. A product sold in that form, understood by both parties to be destined for injection, is the same category of risk.
A ‘research use only’ or ‘not for human consumption’ label does not make a product authorised or suitable for injection in humans.
Why is sterility such a concern?
Because the product is injected under the skin. Sterile manufacture requires controlled conditions, and contamination or endotoxins in an injected product can cause serious infection.
This cannot be assessed by looking at a vial.
I used one and felt fine. Does that mean it was genuine?
Not necessarily. It may have contained less active substance than claimed, a different amount than intended, or impurities with no immediate effect.
Mention it at your next appointment, particularly if you are considering licensed treatment.
What should I do if I feel unwell after using one?
Seek medical advice and say exactly what you took and when. Bring the packaging if you have it.
Seek urgent attention for symptoms of low blood sugar, severe stomach pain spreading to your back, swelling of the face or throat, difficulty breathing, or signs of infection at an injection site.
Can I report a product I think was fake?
Yes. Suspected counterfeit or unlicensed medicines can be reported to the MHRA, and suspected side effects can be reported through the Yellow Card scheme.
Keep the product and packaging, as both are useful.
Beyond the Scale: Weight Loss and Organ Health
Types of Prescription Weight Loss Medicines in the UK
Related Posts
Protecting Muscle During Rapid Weight Loss
Beyond the Scale: Weight Loss and Organ Health
Ozempic or Mounjaro? What Applies in the UK
